A5031259441- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Breast Lesions and Carcinomas
China Medical University
2022-2025
Capital Medical University
2023
Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates moderate objective (ORR) hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor radiotherapy preclinical studies, this pilot study aimed to explore the efficacy safety stereotactic body radiation (SBRT)...
Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates moderate objective (ORR) hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor radiotherapy preclinical studies, this pilot study aimed to explore the efficacy safety stereotactic body radiation (SBRT)...
Abstract Significant heterogeneity exists in hormone receptor (HR)-positive/HER2-positive (HR + /HER2 ) breast cancer, contributing to suboptimal pathological complete response rates with conventional neoadjuvant treatment regimens. Overcoming this challenge requires precise molecular classification, which is pivotal for the development of targeted therapies. We conducted typing on a cohort 211 patients HR cancer and performed comprehensive analysis efficacy various Our findings revealed...
Current therapies for HER2-positive breast cancer have limited efficacy in patients with triple-positive (TPBC). We conduct a multi-center single-arm phase 2 trial to test the and safety of an oral neoadjuvant therapy pyrotinib, letrozole dalpiciclib (a CDK4/6 inhibitor) treatment-naïve, stage II-III TPBC Karnofsky score ≥70 (NCT04486911). The primary endpoint is proportion pathological complete response (pCR) axilla. secondary endpoints include residual burden (RCB)-0 or RCB-I, objective...
Abstract Triple‐positive breast cancer (TPBC) poorly responds to current standard neoadjuvant therapy (trastuzumab plus pertuzumab and chemotherapy). Our previous MUKDEN 01 study showed a promising total pathological complete response (tpCR) rate of 30.4% with pyrotinib (pan‐human epidermal growth factor receptor tyrosine kinase inhibitor) dalpiciclib (cyclin‐dependent 4/6 letrozole, but the efficacy remains suboptimal. This pilot (NCT05228951) explored adding trastuzumab this triplet...
Abstract Background Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates moderate objective (ORR) hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor radiotherapy preclinical studies, this pilot study aimed to explore the efficacy safety stereotactic body...
e12603 Background: Our previous MUKDEN 01 study showed a promising total pathological complete response (tpCR) rate of 30.4% with neoadjuvant pyrotinib plus dalpiciclib (cyclin dependent kinase 4/6 inhibitor) and letrozole in patients triple-positive breast cancer (TPBC), but the efficacy still needs improvement. This pilot explored safety adding trastuzumab to this regimen TPBC. Methods: Patients received five 28-day cycles (320 mg once daily), (125 daily on days 1-21) (2.5 six 21-day (8...
Abstract Background Breast mucinous adenocarcinoma is a group of malignant tumors epithelial origin the breast with good prognosis; however, whether its treatment regimen should be consistent that non-specific types cancer remains to investigated. Methods In this study, clinicopathological information, modalities, and prognosis 10,466 patients from Surveillance, Epidemiology, End Results (SEER) database were analyzed. After adjusting for other factors, radiotherapy showed favorable benefit...
e12604 Background: Despite cyclin dependent kinase 4/6 (CDK4/6) inhibitors having revolutionized treatment for advanced hormone receptor (HR)-positive, HER2-negative (HR+/HER2-) breast cancer, it still has limited efficacy in the neoadjuvant setting. Preclinical studies have indicated radiotherapy followed by CDK4/6 can enhance antineoplastic effects. Stereotactic body (SBRT) is more effective than conventional fractionation. This MUKDEN 03 pilot study aimed to explore and safety of a...